CN114376932A - Composition for improving stimulation of gamma-aminobutyric acid and preparation method and application thereof - Google Patents
Composition for improving stimulation of gamma-aminobutyric acid and preparation method and application thereof Download PDFInfo
- Publication number
- CN114376932A CN114376932A CN202210181017.6A CN202210181017A CN114376932A CN 114376932 A CN114376932 A CN 114376932A CN 202210181017 A CN202210181017 A CN 202210181017A CN 114376932 A CN114376932 A CN 114376932A
- Authority
- CN
- China
- Prior art keywords
- composition
- humectant
- gamma
- aminobutyric acid
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 title claims abstract description 166
- 229960003692 gamma aminobutyric acid Drugs 0.000 title claims abstract description 82
- 239000000203 mixture Substances 0.000 title claims abstract description 82
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 title claims abstract description 81
- 230000000638 stimulation Effects 0.000 title claims abstract description 12
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- 239000003906 humectant Substances 0.000 claims abstract description 43
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 18
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 65
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 38
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 38
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 36
- 239000004202 carbamide Substances 0.000 claims description 34
- 229920001503 Glucan Polymers 0.000 claims description 32
- QCYLIQBVLZBPNK-UHFFFAOYSA-N asiaticoside A Natural products O1C(C(=O)C(C)C)=CC(C)C(C2(C(OC(C)=O)CC34C5)C)C1CC2(C)C3CCC(C1(C)C)C45CCC1OC1OCC(O)C(O)C1O QCYLIQBVLZBPNK-UHFFFAOYSA-N 0.000 claims description 31
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 29
- WYQVAPGDARQUBT-FGWHUCSPSA-N Madecassol Chemical compound O([C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)O)OC[C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)OC(=O)[C@]12CC[C@H]([C@@H]([C@H]1C=1[C@@]([C@@]3(CC[C@H]4[C@](C)(CO)[C@@H](O)[C@H](O)C[C@]4(C)[C@H]3CC=1)C)(C)CC2)C)C)[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O WYQVAPGDARQUBT-FGWHUCSPSA-N 0.000 claims description 29
- 108010020346 Polyglutamic Acid Proteins 0.000 claims description 29
- WYQVAPGDARQUBT-XCWYDTOWSA-N asiaticoside Natural products O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@H](O)[C@H](O[C@H]3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)[C@@H](CO)O2)O1)[C@@]12[C@@H]([C@@H](C)[C@H](C)CC1)C=1[C@](C)([C@@]3(C)[C@@H]([C@@]4(C)[C@H]([C@@](CO)(C)[C@@H](O)[C@H](O)C4)CC3)CC=1)CC2 WYQVAPGDARQUBT-XCWYDTOWSA-N 0.000 claims description 29
- 229940022757 asiaticoside Drugs 0.000 claims description 29
- 229910052708 sodium Inorganic materials 0.000 claims description 29
- 239000011734 sodium Substances 0.000 claims description 29
- 229920000370 gamma-poly(glutamate) polymer Polymers 0.000 claims description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 23
- 239000002537 cosmetic Substances 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 12
- 238000003756 stirring Methods 0.000 claims description 10
- 239000006071 cream Substances 0.000 claims description 8
- 230000003020 moisturizing effect Effects 0.000 claims description 8
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 claims description 6
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 claims description 6
- 230000001153 anti-wrinkle effect Effects 0.000 claims description 6
- 229940106189 ceramide Drugs 0.000 claims description 6
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 claims description 6
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 claims description 6
- 235000011399 aloe vera Nutrition 0.000 claims description 5
- 239000000284 extract Substances 0.000 claims description 5
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 4
- 230000002087 whitening effect Effects 0.000 claims description 4
- 239000006210 lotion Substances 0.000 claims description 3
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims description 2
- CCOQPGVQAWPUPE-UHFFFAOYSA-N 4-tert-butylcyclohexan-1-ol Chemical compound CC(C)(C)C1CCC(O)CC1 CCOQPGVQAWPUPE-UHFFFAOYSA-N 0.000 claims description 2
- 229940091886 4-tert-butylcyclohexanol Drugs 0.000 claims description 2
- 235000002961 Aloe barbadensis Nutrition 0.000 claims description 2
- 244000186892 Aloe vera Species 0.000 claims description 2
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 2
- 229920002678 cellulose Polymers 0.000 claims description 2
- 239000001913 cellulose Substances 0.000 claims description 2
- 229940041616 menthol Drugs 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 125000000647 trehalose group Chemical group 0.000 claims description 2
- 241001071795 Gentiana Species 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 150000003384 small molecules Chemical class 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 44
- 230000037303 wrinkles Effects 0.000 abstract description 31
- 230000002195 synergetic effect Effects 0.000 abstract description 8
- 238000013329 compounding Methods 0.000 abstract description 5
- 239000002994 raw material Substances 0.000 abstract description 3
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 210000003491 skin Anatomy 0.000 description 35
- 229940074410 trehalose Drugs 0.000 description 35
- 206010040954 Skin wrinkling Diseases 0.000 description 32
- 208000002193 Pain Diseases 0.000 description 14
- 238000012360 testing method Methods 0.000 description 13
- 238000001816 cooling Methods 0.000 description 9
- 230000035807 sensation Effects 0.000 description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 7
- 230000014759 maintenance of location Effects 0.000 description 7
- 230000036407 pain Effects 0.000 description 6
- 208000035824 paresthesia Diseases 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 150000001720 carbohydrates Chemical class 0.000 description 5
- 235000014633 carbohydrates Nutrition 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 4
- 108010035532 Collagen Proteins 0.000 description 4
- 230000003266 anti-allergic effect Effects 0.000 description 4
- 239000011449 brick Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- 230000001815 facial effect Effects 0.000 description 4
- 229920002674 hyaluronan Polymers 0.000 description 4
- 229960003160 hyaluronic acid Drugs 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 241001116389 Aloe Species 0.000 description 3
- 102000016942 Elastin Human genes 0.000 description 3
- 108010014258 Elastin Proteins 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 208000003251 Pruritus Diseases 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- -1 amino acid anion Chemical class 0.000 description 3
- 230000000202 analgesic effect Effects 0.000 description 3
- 239000003181 biological factor Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229920002549 elastin Polymers 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000007803 itching Effects 0.000 description 3
- 229920006008 lipopolysaccharide Polymers 0.000 description 3
- 229920002643 polyglutamic acid Polymers 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 235000004866 D-panthenol Nutrition 0.000 description 2
- 239000011703 D-panthenol Substances 0.000 description 2
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- BNMGUJRJUUDLHW-HCZMHFOYSA-N Madecassoside Chemical compound O([C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)O)OC[C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)OC(=O)[C@]12CC[C@H]([C@@H]([C@H]1C=1[C@@]([C@@]3(C[C@@H](O)[C@H]4[C@](C)(CO)[C@@H](O)[C@H](O)C[C@]4(C)[C@H]3CC=1)C)(C)CC2)C)C)[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O BNMGUJRJUUDLHW-HCZMHFOYSA-N 0.000 description 2
- BNMGUJRJUUDLHW-HLUHVYOBSA-N Madecassoside Natural products C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]5[C@H](O)C[C@@]34C)[C@@H]2[C@H]1C)C(=O)O[C@@H]6O[C@H](CO[C@@H]7O[C@H](CO)[C@@H](O[C@@H]8O[C@H](C)[C@H](O)[C@@H](O)[C@H]8O)[C@H](O)[C@H]7O)[C@@H](O)[C@H](O)[C@H]6O BNMGUJRJUUDLHW-HLUHVYOBSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 208000000114 Pain Threshold Diseases 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 229940124277 aminobutyric acid Drugs 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 229960003949 dexpanthenol Drugs 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 2
- VKOBVWXKNCXXDE-UHFFFAOYSA-N icosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCC(O)=O VKOBVWXKNCXXDE-UHFFFAOYSA-N 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 229940090813 madecassoside Drugs 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000037040 pain threshold Effects 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 239000012466 permeate Substances 0.000 description 2
- 239000000419 plant extract Substances 0.000 description 2
- 108700022290 poly(gamma-glutamic acid) Proteins 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000000979 retarding effect Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 230000037307 sensitive skin Effects 0.000 description 2
- 230000037075 skin appearance Effects 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 229960000401 tranexamic acid Drugs 0.000 description 2
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 description 2
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 2
- WTVHAMTYZJGJLJ-UHFFFAOYSA-N (+)-(4S,8R)-8-epi-beta-bisabolol Natural products CC(C)=CCCC(C)C1(O)CCC(C)=CC1 WTVHAMTYZJGJLJ-UHFFFAOYSA-N 0.000 description 1
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- RGZSQWQPBWRIAQ-CABCVRRESA-N (-)-alpha-Bisabolol Chemical compound CC(C)=CCC[C@](C)(O)[C@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-CABCVRRESA-N 0.000 description 1
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 229920002498 Beta-glucan Polymers 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- 206010006784 Burning sensation Diseases 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- IMXSCCDUAFEIOE-UHFFFAOYSA-N D-Octopin Natural products OC(=O)C(C)NC(C(O)=O)CCCN=C(N)N IMXSCCDUAFEIOE-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- IMXSCCDUAFEIOE-RITPCOANSA-N D-octopine Chemical compound [O-]C(=O)[C@@H](C)[NH2+][C@H](C([O-])=O)CCCNC(N)=[NH2+] IMXSCCDUAFEIOE-RITPCOANSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- AFSDNFLWKVMVRB-UHFFFAOYSA-N Ellagic acid Chemical compound OC1=C(O)C(OC2=O)=C3C4=C2C=C(O)C(O)=C4OC(=O)C3=C1 AFSDNFLWKVMVRB-UHFFFAOYSA-N 0.000 description 1
- ATJXMQHAMYVHRX-CPCISQLKSA-N Ellagic acid Natural products OC1=C(O)[C@H]2OC(=O)c3cc(O)c(O)c4OC(=O)C(=C1)[C@H]2c34 ATJXMQHAMYVHRX-CPCISQLKSA-N 0.000 description 1
- 229920002079 Ellagic acid Polymers 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 208000004454 Hyperalgesia Diseases 0.000 description 1
- 208000035154 Hyperesthesia Diseases 0.000 description 1
- 208000004044 Hypesthesia Diseases 0.000 description 1
- 229940124091 Keratolytic Drugs 0.000 description 1
- HXEACLLIILLPRG-YFKPBYRVSA-N L-pipecolic acid Chemical compound [O-]C(=O)[C@@H]1CCCC[NH2+]1 HXEACLLIILLPRG-YFKPBYRVSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 1
- LBBBWHJWPKKHAK-UHFFFAOYSA-N Ruscin Natural products O1C2(OCC(=C)CC2)C(C)C(C2(CCC3C4(C)C(O)C5)C)C1CC2C3CC=C4CC5OC1OCC(O)C(O)C1OC(C1O)OC(C)C(O)C1OC1OC(CO)C(O)C(O)C1O LBBBWHJWPKKHAK-UHFFFAOYSA-N 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 102000003425 Tyrosinase Human genes 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- RGZSQWQPBWRIAQ-LSDHHAIUSA-N alpha-Bisabolol Natural products CC(C)=CCC[C@@](C)(O)[C@@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-LSDHHAIUSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000001139 anti-pruritic effect Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229960000271 arbutin Drugs 0.000 description 1
- 229940011658 asiatic acid Drugs 0.000 description 1
- JXSVIVRDWWRQRT-UYDOISQJSA-N asiatic acid Chemical compound C1[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C JXSVIVRDWWRQRT-UYDOISQJSA-N 0.000 description 1
- LBGFKBYMNRAMFC-PYSQTNCISA-N asiatic acid Natural products C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]5CC[C@@]34C)[C@]2(C)[C@H]1C)C(=O)O LBGFKBYMNRAMFC-PYSQTNCISA-N 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229940036350 bisabolol Drugs 0.000 description 1
- HHGZABIIYIWLGA-UHFFFAOYSA-N bisabolol Natural products CC1CCC(C(C)(O)CCC=C(C)C)CC1 HHGZABIIYIWLGA-UHFFFAOYSA-N 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229940045110 chitosan Drugs 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 229960005188 collagen Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229960002852 ellagic acid Drugs 0.000 description 1
- 235000004132 ellagic acid Nutrition 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- CLXOLTFMHAXJST-UHFFFAOYSA-N esculentic acid Natural products C12CC=C3C4CC(C)(C(O)=O)CCC4(C(O)=O)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(CO)C CLXOLTFMHAXJST-UHFFFAOYSA-N 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 210000000887 face Anatomy 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 1
- 229940114124 ferulic acid Drugs 0.000 description 1
- 235000001785 ferulic acid Nutrition 0.000 description 1
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 238000011990 functional testing Methods 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 229960004275 glycolic acid Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 208000034783 hypoesthesia Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000001530 keratinolytic effect Effects 0.000 description 1
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 1
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 1
- 229960004705 kojic acid Drugs 0.000 description 1
- HXEACLLIILLPRG-RXMQYKEDSA-N l-pipecolic acid Natural products OC(=O)[C@H]1CCCCN1 HXEACLLIILLPRG-RXMQYKEDSA-N 0.000 description 1
- 210000001821 langerhans cell Anatomy 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 description 1
- 235000019136 lipoic acid Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229940099690 malic acid Drugs 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000008099 melanin synthesis Effects 0.000 description 1
- FAARLWTXUUQFSN-UHFFFAOYSA-N methylellagic acid Natural products O1C(=O)C2=CC(O)=C(O)C3=C2C2=C1C(OC)=C(O)C=C2C(=O)O3 FAARLWTXUUQFSN-UHFFFAOYSA-N 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- 235000013557 nattō Nutrition 0.000 description 1
- 210000000944 nerve tissue Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 150000002840 non-reducing disaccharides Chemical class 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 150000002966 pentacyclic triterpenoids Chemical class 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 229940064064 purslane extract Drugs 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- KEBKEYDWZYNHHS-KNQIUGTDSA-N ruscin Chemical compound O([C@@H]1[C@@H](O)[C@H](C)O[C@H]([C@@H]1O)O[C@@H]1[C@@H](O)[C@@H](O)CO[C@H]1O[C@@H]1C[C@H](O)CC2=CC[C@H]3[C@@H]4C[C@H]5[C@@H]([C@]4(CC[C@@H]3[C@]21C)C)[C@@H]([C@]1(OCC(=C)CC1)O5)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O KEBKEYDWZYNHHS-KNQIUGTDSA-N 0.000 description 1
- KEBKEYDWZYNHHS-UHFFFAOYSA-N ruscoponticoside D Natural products O1C2(OCC(=C)CC2)C(C)C(C2(CCC3C45C)C)C1CC2C3CC=C4CC(O)CC5OC1OCC(O)C(O)C1OC(C1O)OC(C)C(O)C1OC1OC(CO)C(O)C(O)C1O KEBKEYDWZYNHHS-UHFFFAOYSA-N 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 230000037384 skin absorption Effects 0.000 description 1
- 231100000274 skin absorption Toxicity 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229960004274 stearic acid Drugs 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229960002663 thioctic acid Drugs 0.000 description 1
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 150000008130 triterpenoid saponins Chemical class 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/42—Amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/602—Glycosides, e.g. rutin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/88—Polyamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/70—Biological properties of the composition as a whole
- A61K2800/72—Hypo-allergenic
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Cosmetics (AREA)
Abstract
The invention provides a composition for improving stimulation of gamma-aminobutyric acid, and a preparation method and application thereof. The composition comprises the gamma-aminobutyric acid, the macromolecular humectant, the micromolecular humectant and the soothing agent, and can effectively relieve instant discomfort, especially tingling, brought by the use of the gamma-aminobutyric acid through the synergistic compounding of the gamma-aminobutyric acid, the macromolecular humectant, the micromolecular humectant and the soothing agent, so that the safe dosage of the gamma-aminobutyric acid is improved. In addition, the composition has better effects of resisting wrinkles and removing wrinkles. The composition has the advantages of simple preparation, easily obtained raw materials, low cost, and convenient popularization, application and commercial production.
Description
Technical Field
The application relates to the field of cosmetics, in particular to a composition for improving stimulation of gamma-aminobutyric acid and a preparation method and application thereof.
Background
Wrinkle resistance, wrinkle removal and aging delay are topics which are unchangeable after the ancient times of people who love beauty. With the aging and external environmental influences, wrinkles appear on the forehead, the upper and lower eyelids, the outer canthus, the anterior auricular region, the cheek, the neck, the chin, the periphery of the mouth, etc. From ancient times to date, various methods have been tried to delay the development of wrinkles, and most of these methods have been slow in effectiveness or have received little effect.
Gamma-aminobutyric acid (GABA), also known as aminobutyric acid, 4-aminobutyric acid, pipecolic acid, having a molecular formula of C4H9NO2The molecular weight is 103.1. Gamma-aminobutyric acid is an inhibitory neurotransmitter of the central nervous system of mammals, is widely distributed in prokaryotes and eukaryotes, and has been proved to have the effects of relieving anxiety, lowering blood pressure, improving sleep, removing wrinkles and whitening. When the wrinkle is removed, the gamma-aminobutyric acid can relax tight muscle nerve tissues, quickly penetrate through skin, fade fine wrinkles, enhance the relaxation function of muscles and play a role in quickly removing wrinkles.
By utilizing the property of the gamma-aminobutyric acid, a series of products such as facial masks, face creams, eye creams and the like are developed abroad and used in the wrinkle removing field, but the gamma-aminobutyric acid has certain side effect, namely uncomfortable symptoms such as tingling, numbness, itching, burning and the like can be generated when the high-concentration gamma-aminobutyric acid is contacted with the skin, and the side effect has positive correlation with the concentration of the gamma-aminobutyric acid. At present, the content of gamma-aminobutyric acid in cosmetics is recommended to be up to 5.0%. Under the limitation of the side effect of the gamma-aminobutyric acid, the product of the gamma-aminobutyric acid cannot reach the expected wrinkle removing concentration, so that the wrinkle removing effect of the gamma-aminobutyric acid and the wide application of the gamma-aminobutyric acid in the wrinkle removing field are limited to a certain extent.
Chinese patent CN105362091A discloses a composition containing gamma-aminobutyric acid and hyaluronic acid and its application in cosmetics, which, although the side effects of gamma-aminobutyric acid are slowed to some extent, has a single composition and still needs to be improved.
Disclosure of Invention
The invention aims to provide a composition containing gamma-aminobutyric acid, which slows down the side effect of the gamma-aminobutyric acid in use, especially reduces the tingling feeling, safely improves the dosage of the gamma-aminobutyric acid, and has good synergistic effect, and better effects of resisting wrinkles, removing wrinkles and preserving moisture.
On one hand, the application provides a composition for improving stimulation of gamma-aminobutyric acid, and the composition comprises 1-10 parts of gamma-aminobutyric acid, 1-20 parts of macromolecular humectant, 1-20 parts of micromolecular humectant and 0.1-10 parts of soothing agent by weight;
the molecular weight of the macromolecular humectant is 100-200 ten thousand daltons, and the molecular weight of the micromolecular humectant is less than 1000 daltons.
Further, the composition comprises 1-4 parts of gamma-aminobutyric acid, 1-5 parts of macromolecular humectant, 1-5 parts of micromolecular humectant and 1-2 parts of soothing agent; preferably, 3 parts of gamma-aminobutyric acid, 4 parts of macromolecular humectant, 4 parts of micromolecular humectant and 1 part of soothing agent.
Further, the macromolecular humectant is selected from one or more of biogel-1, oat glucan, sodium polyglutamate and cellulose sulfate; preferably, the macromolecular humectant comprises bioglycan-1, oat glucan and sodium polyglutamate; more preferably, the mass ratio of the biological sugar gum-1 to the oat glucan to the sodium polyglutamate is (1-5): (1-5): (1-10); more preferably, the mass ratio of the biological sugar gum-1, the oat glucan and the sodium polyglutamate is 1:1: 2.
further, the small molecular humectant is selected from one or more of trehalose, urea, menthol lactate, 4-tert-butylcyclohexanol, water-soluble ceramide and aloe juice; preferably, the micromolecular humectant is trehalose and urea; more preferably, the mass ratio of the trehalose to the urea is (1-10): (1-10); more preferably, the mass ratio of the trehalose to the urea is 1: 1.
further, the soothing agent is selected from one or more of asiaticoside and radix gentianae extract; more preferably, the soothing agent is asiaticoside.
The macromolecular humectant biogum-1, the sodium polyglutamate and the beta glucan play a role in slow release for permeation of gamma-aminobutyric acid, stimulation of the gamma-aminobutyric acid to skin is relieved, the micromolecular humectants urea and trehalose can permeate into the skin to rapidly expand the skin, the macromolecular humectant is matched to play a role in moisturizing, wrinkle removing and stimulation reducing, and the asiaticoside has good effects of relieving and pain relieving for the skin. The multiple effects take effect simultaneously, so that the composition can achieve better effects of resisting wrinkles and removing wrinkles while reducing side effects caused by gamma-aminobutyric acid.
In another aspect, the present application also provides a method of preparing a composition, the method comprising the steps of: the preparation method comprises the following steps: mixing and dissolving gamma-aminobutyric acid, a macromolecular humectant, a micromolecular humectant and a soothing agent by using water at the temperature of 40-70 ℃, and uniformly stirring to obtain the composition; preferably, the total amount is 100 parts by mass with water.
On the other hand, the application also provides the application of the composition or the composition obtained by the preparation method in wrinkle resistance, wrinkle removal, whitening and/or moisture retention; preferably, the composition is used for anti-wrinkle and wrinkle-removal.
In another aspect, the present application also provides a cosmetic comprising the above composition or the composition prepared by the above method.
Further, the content of the gamma-aminobutyric acid in the cosmetic is 0.1-15% by mass, preferably 0.5-15% by mass, and more preferably 5.1-15% by mass.
Further, the cosmetic is a mask, a cream, an emulsion, an essence, a lotion, an eye cream and/or an introduction solution.
Wherein, the sodium polyglutamate is an amino acid anion polymer with viscosity, which is discovered from natto at first, and is also called as gamma-PGA, has excellent skin care and maintenance efficacies, and promotes the synthesis of natural skin moisturizing factor PCA; inhibiting tyrosinase activity and reducing melanin synthesis; the fibroblast is activated to synthesize collagen and elastin, so that the skin is elastic, more moist and bright. The gamma-PGA can be used for constructing an embedding sustained-release system, promoting skin absorption, forming a film on the surface of the skin, isolating environmental stimulation and reducing skin inflammation.
Biosaccharide gum-1 is a linear biopolymer ((R))>106Daltons). The biological carbohydrate gum-1 has strong water binding capacity, has good water absorption effect even in a low-humidity environment, and forms a breathable sugar film on the surface layer of the skin. Preventing the skin moisture from evaporating again, and simultaneously having instant and long-acting moisturizing effect. The cosmetic not only has the effects of moisturizing and relieving, but also gives soft and smooth skin feeling to the cosmetic product, and provides more choices of high-quality raw materials for a cosmetic formulator.
Oat glucan can penetrate into skin, and has obvious penetration phenomenon to both horny layer and epidermal layer. The penetration method of oat glucan is not to penetrate cells directly, but to penetrate into the skin through intercellular spaces. As water penetrates into the brick wall, it does not penetrate through the brick body, but through the concrete connecting the brick bodies. Oat glucan permeates into the skin lining through intercellular lipid matrix, also called intercellular concrete. This is in good balance with the "brick mud model" theory of skin. Since oat glucan can promote the proliferation of Langerhans cells so as to enhance the immunocompetence of the skin, clinical researches also show that the oat glucan also has remarkable anti-inflammatory and anti-allergic activities and can help the skin to resist various exogenous mechanical and chemical stimuli. Oat glucan skin activator is a highly purified cell extract, and oat glucan is actually recognized by receptors on immunocompetent cell membranes and activates immunocompetent cells. Oat glucan increases Epidermal Growth Factor (EGF) on aged skin and wrinkled skin, and promotes increase of collagen and elastin in skin, thereby improving skin appearance and removing wrinkles. The skin activator is a highly purified cell extract, and the fact that oat glucan is recognized by receptors on immunocompetent cell membranes and activates immunocompetent cells. Oat glucan increases Epidermal Growth Factor (EGF) on aged skin and wrinkled skin, and promotes increase of collagen and elastin in skin, thereby improving skin appearance and removing wrinkles.
Asiaticoside belongs to pentacyclic triterpenoid, and mainly comprises asiaticoside, madecassoside, asiatic acid, a few trace triterpenoid saponins and the like. Has various pharmacological effects of resisting ulcer, promoting wound healing, resisting tumor, resisting inflammation, regulating immunity, etc. The Mingzhijun and the like find that the asiaticoside 12, 6 and 3mg/kg can prolong the pain threshold reaction time of the mice to thermal stimulation and reduce the frequency of writhing reaction to glacial acetic acid. The asiaticoside is proved to have analgesic effect (reference document: Mingzhi, Sunpeng. asiaticoside has analgesic effect on mouse [ J ] Chinese medicine, 2001,29(6): 2.). Octopun et al observed the effect of asiaticoside on the induction of hyperalgesia by ip Lipopolysaccharide (LPS) in mice. Compared with a model group, 45 mg/kg, 15 mg/kg and 5mg/kg of asiaticoside can obviously reduce the times of mouse writhing reaction, improve pain threshold, and obviously reduce the MPO activity, NO content and plasma TNF-alpha content of brain tissues (P is less than 0.01 and 0.05) (references: octopine, Wanjingdan, Luofingling, and the like.) the asiaticoside has the effects of sensitizing the mouse lipopolysaccharide to pain sense and influencing MPO, NO and TNF-alpha [ J ] Chinese pharmaceutical journal, 2008,43(10):3 ]. The above studies suggest that asiaticoside, asiaticoside and madecassoside all have analgesic effects, and the action mechanisms of the latter two monomeric components may be related to the inhibition of inflammatory reaction.
Urea is the final product of protein metabolism and is a physiological substance of the human body. The total daily excretion amount of human is about 30 g. Wherein the urea content of the skin is about 1%. Urea affects the ability of the stratum corneum to bind moisture, is one of the natural moisturizing factors, and also has keratolytic, penetration-promoting, antimicrobial and anti-pruritic effects.
Trehalose is a non-reducing disaccharide commonly existing in organisms in the nature, is formed by connecting two molecules of pyranoglucose ring through alpha, alpha-1, 1-glycosidic bond, and has very stable chemical properties. 1, 2-trehalose has unique and excellent biological protective properties different from other disaccharides, and is capable of effectively protecting biomacromolecule structures from being damaged under extremely severe conditions (high temperature, extreme pH, high osmotic pressure, dryness, etc.), thereby maintaining the life process of organisms. The moisture retention rate reduction rate of trehalose under two relative humidities (62% and 85%) is close to that of glycerin, so that the relative moisture retention Rate (RME) of trehalose under two relative humidities is relatively stable, and therefore when a moisture retention agent with the moisture retention capacity similar to that of glycerin is needed, the defect of water absorption to skin is avoided, and trehalose with a proper concentration can be selected; the results show that RME of trehalose at 62% RH (relative humidity) for 4h is highest in 5 samples (49.13), with significant differences from aloe vera juice, biological factors, hyaluronic acid, ceramide. There were also significant differences in RME of aloe juice, biological factors, whereas the relative moisture retention rate differences of hyaluronic acid and ceramide were not significantly 10.54 and 10.06, respectively. According to the significance difference, the moisture retention performance is arranged from high to low as: trehalose, aloe juice, biological factor, hyaluronic acid, ceramide (reference: Qinlong, Wangchang, He clever, etc.. evaluation of in vitro moisturizing function of single moisturizer [ J ] daily chemical industry, 2006,36(3): 3.).
Optionally, the active ingredients of the composition of the present application may be only γ -aminobutyric acid and the macromolecular humectant, the small molecular humectant and the soothing agent, or some other active ingredients may be added based on the γ -aminobutyric acid and the macromolecular humectant, the small molecular humectant and the soothing agent to enhance the effects of anti-wrinkle, moisturizing, whitening, repairing, etc., such as small molecular peptides, collagen, betaine, squalane, trehalose, butylene glycol, complex amino acids, glycerol, creatine, tranexamic acid, D-panthenol, niacinamide, ferulic acid, lipoic acid, plant extracts, chitosan, chondroitin sulfate, heparin, ceramide, lecithin, vaseline, stearic acid, arachidic acid, hexadecyl ester, etc.; the composition can also be added with other effective components with other functions disclosed in the prior art to increase the diversity of the efficacy of the composition, for example, freckle removing effective components (specifically, tranexamic acid, arbutin, kojic acid, ellagic acid, ruscin, vitamin C and derivatives thereof, placenta and the like can be selected), acne removing effective components (specifically, tretinoin, glycolic acid, salicylic acid, malic acid, citric acid and the like can be selected), anti-allergy effective components (specifically, D-panthenol, bisabolol, glycyrrhetinic acid, allantoin, purslane extract, dipotassium glycyrrhizinate, vitamin E, plant extracts and the like can be selected), and other skin care effective components which are disclosed in the prior art and can be compounded with gamma-aminobutyric acid to achieve the synergistic effect.
The invention has the following beneficial effects:
1. experiments prove that the composition can effectively relieve the discomfort, especially the sting feeling, caused by the use of the gamma-aminobutyric acid by the synergistic compounding of the sodium polyglutamate, the biological carbohydrate gum-1, the oat glucan, the trehalose, the urea and the asiaticoside, overcomes the adverse stimulation of the high-concentration gamma-aminobutyric acid on the skin by the single use of the gamma-aminobutyric acid, and provides a new compounding combination for the gamma-aminobutyric acid.
2. The composition improves the safe use content of the gamma-aminobutyric acid in the cosmetics, and improves the content of the gamma-aminobutyric acid in the cosmetics to 5.1-15% in percentage by mass.
3. The components in the composition have good synergistic effect, the anti-wrinkle and wrinkle-removing effects of the composition are improved while the side effect of the gamma-aminobutyric acid is effectively relieved, and a novel efficient anti-wrinkle and wrinkle-removing composition is provided.
4. The composition is suitable for preparing various cosmetics such as facial masks, face creams, emulsions, essence water, eye creams and introduction liquid, and is simple to prepare, low in cost, convenient to popularize and use and convenient for commercial production, and raw materials are easy to obtain.
Detailed Description
In order to more clearly explain the overall concept of the present application, the following detailed description is given by way of example. In the following description, numerous specific details are set forth in order to provide a more thorough understanding of the present invention. It will be apparent, however, to one skilled in the art, that the present invention may be practiced without one or more of these specific details. In other instances, well-known features have not been described in order to avoid obscuring the invention.
The examples, in which specific conditions are not specified, were conducted under conventional conditions or conditions recommended by the manufacturer.
Wherein the radix Gentianae extract is prepared by Shanghai Gayu Biotech limited company, and is extracted from wild radix Gentianae in Xizang Linzhou county; gamma-aminobutyric acid is provided by Sichuan Tong Cheng amino acid GmbH; the biological sugar gum-1 is provided by Henan Baikang chemical products Co., Ltd, and has a molecular weight of 100-200 ten thousand daltons; the polyglutamic acid sodium is provided by Wuhan Guanghua times biological technology limited company, and the molecular weight is 100-150 kilodaltons; the oat glucan is provided by Xian Zhongying science and technology development limited company, and the molecular weight is 100-200 ten thousand daltons; asiaticoside is provided by Shanghai Fenghui biological science and technology limited; trehalose is supplied by Shanghai-derived Biotech, Inc. and has a molecular weight of 378.33 daltons; urea is supplied by Tech technologies, Inc. of Yinaoka, Beijing, and has a molecular weight of 60.06 daltons; VISIA skin tester is available from Canfield technologies.
In the following embodiments, reagents or instruments used are not indicated by manufacturers, and are all conventional products available by commercial purchase, unless otherwise specified.
EXAMPLE 1 composition ingredient screening
In order to reduce adverse side effects of gamma-aminobutyric acid, 3% of gamma-aminobutyric acid in percentage by mass is compounded with different components, and the balance of water is fully and uniformly mixed at room temperature and then tested.
160 volunteers were searched, and the ages and sexes of the volunteers were randomly determined to meet the standards of the cosmetic hygiene code (2007 edition). And (3) placing 1mL of sample in nasolabial sulcus on two sides of a subject, using a 3% aminobutyric acid aqueous solution as a control group on one side, using gamma-aminobutyric acid compounded with different components on the other side, cleaning after 10-20 minutes, and observing whether a reaction or a delayed reaction occurs within 30 minutes after neutralization. The results are shown in Table 1.
TABLE 1 composition component screening
In conclusion, as can be seen from the data in table 1, in a single compounding experiment, the gamma-aminobutyric acid has a good effect when being compounded with oat glucan, sodium polyglutamate, bioglycan-1, trehalose, urea and asiaticoside, and the pricking feeling is obviously relieved.
Further, oat glucan, sodium polyglutamate, biological carbohydrate gum-1, trehalose, urea and asiaticoside are combined for compound experiments. In the application, the side effect retarding effect of the gamma-aminobutyric acid is obviously retarded when the composition is compounded compared with that of a single component, and particularly, the side effect retarding effect is optimal when all the components are compounded together. Proves that the oat glucan, the sodium polyglutamate, the biological carbohydrate gum-1, the trehalose, the urea and the asiaticoside have good synergistic effect when being compounded with the gamma-aminobutyric acid, and can greatly reduce the pain caused by the gamma-aminobutyric acid.
Composition 1
Putting 3g of gamma-aminobutyric acid, 2g of bioglycan-1, 2g of oat glucan, 4g of sodium polyglutamate, 2g of trehalose, 2g of urea and 84g of deionized water into a beaker, stirring and heating to 60 ℃ until the sodium polyglutamate, the trehalose, the urea and the deionized water are completely dissolved, adding 1g of asiaticoside when the temperature is reduced to 40 ℃, stirring and dissolving, and then cooling to room temperature for later use.
Composition 2
Putting 3g of gamma-aminobutyric acid, 1g of bioglycan-1, 1g of oat glucan, 2g of sodium polyglutamate, 2g of trehalose, 2g of urea and 88g of water into a beaker, stirring and heating to 60 ℃ until the sodium polyglutamate, the trehalose, the urea and the water are completely dissolved, adding 1g of asiaticoside when the temperature is reduced to 40 ℃, and then cooling to room temperature for later use.
Composition 3
Adding 3g of gamma-aminobutyric acid, 1g of bioglycan-1, 2g of oat glucan, 1g of sodium polyglutamate, 2g of trehalose, 2g of urea and 88g of water into a beaker, stirring and heating to 60 ℃ until the sodium polyglutamate, the trehalose, the urea and the water are completely dissolved, adding 1g of asiaticoside when the temperature is reduced to 40 ℃, and then cooling to room temperature for later use.
Composition 4
Adding 3g of gamma-aminobutyric acid, 1g of bioglycan-1, 1g of oat glucan, 2g of sodium polyglutamate, 2g of trehalose, 1g of urea and 89g of water into a beaker, stirring and heating to 60 ℃ until the sodium polyglutamate, the trehalose, the urea and the water are completely dissolved, adding 1g of asiaticoside when the temperature is reduced to 40 ℃, and then cooling to room temperature for later use.
Composition 5
Adding 3g of gamma-aminobutyric acid, 1g of bioglycan-1, 1g of oat glucan, 2g of sodium polyglutamate, 2g of trehalose, 2g of urea and 88.5g of water into a beaker, stirring and heating to 60 ℃ until the sodium polyglutamate, the trehalose, the urea and the water are completely dissolved, adding 0.5g of asiaticoside when the temperature is reduced to 40 ℃, and then cooling to room temperature for later use.
Composition 6
Fully and uniformly mixing 3g of gamma-aminobutyric acid, 1g of bioglycan-1, 1g of oat glucan, 2g of sodium polyglutamate and 88g of water, fully swelling at 60 ℃, adding 2g of trehalose and 2g of urea, stirring until the trehalose and the urea are completely dissolved, cooling to 40 ℃, adding 1g of asiaticoside, and cooling to room temperature for later use.
Control group
3g of gamma-aminobutyric acid and 97g of water are placed in a beaker, stirred and heated to 60 ℃ until completely dissolved, and then cooled to room temperature for later use.
Example 2 sting sensation test
The test was conducted with reference to the method of "evaluation method of cosmetic applicability to facial sensitive skin" study (reference: Maris, Youging, Cheng Ying, etc., research of cosmetic applicability to facial sensitive skin, J.Med.Med.Med.Med. J.Dermatology, 17 th Vol.1, 2018).
And selecting a subject having uncomfortable feeling on the gamma-aminobutyric acid for testing, and testing after screening for one week. The total number of subjects enrolled was 35. 1mL of the sample was placed in the nasolabial sulcus of both sides of the subject, using the comparative example on one side and the example on the other side. The stinging sensation was evaluated separately. The test sites were evaluated for the degree of discomfort of itching, stinging, burning sensation by the subjects, with sting criteria and scores as follows:
no sensation was assigned a score of 0, a score of slightly tingling, a score of 2 with strong tingling, a score of 3 with slight stinging, and a score of 4 with strong stinging.
Sting score ═ (0min +1min +5min comparative flank sting score) - (0min +1min +5min example flank sting score)
The Wilcoxon signed order test method is adopted for statistical analysis, the level is set to be a which is 0.05, the test mean value is in a beneficial direction, and the test result p is less than 0.05, so that the result is valid.
The specific results of the sting scores for compositions 1-6 and the control are shown in Table 2.
TABLE 2 evaluation of stinging sensation at each time point for compositions 1-6 and control
0min | 1min | 5min | Sum of | |
Composition 1 | 0.05 | 0.19 | 0.37 | 0.61 |
Control group | 0.32 | 0.45 | 0.65 | 1.42 |
Pricking score | 0.27 | 0.26 | 0.28 | 0.81 |
Composition 2 | 0 | 0.05 | 0.1 | 0.15 |
Control group | 0.36 | 0.47 | 0.75 | 1.58 |
Pricking score | 0.36 | 0.42 | 0.65 | 1.43 |
Composition 3 | 0 | 0.12 | 0.14 | 0.26 |
Control group | 0.28 | 0.39 | 0.65 | 1.32 |
Pricking score | 0.28 | 0.27 | 0.51 | 1.06 |
Composition 4 | 0.07 | 0.23 | 0.19 | 0.49 |
Control group | 0.42 | 0.53 | 0.68 | 1.63 |
Pricking score | 0.35 | 0.3 | 0.49 | 1.14 |
Composition 5 | 0.10 | 0.22 | 0.45 | 0.77 |
Control group | 0.31 | 0.57 | 0.68 | 1.56 |
Pricking score | 0.21 | 0.35 | 0.23 | 0.79 |
Composition 6 | 0.04 | 0.13 | 0.20 | 0.37 |
Control group | 0.55 | 0.60 | 0.71 | 1.86 |
Pricking score | 0.51 | 0.47 | 0.51 | 1.49 |
As can be seen from the data of compositions 1-3 in Table 2, the effect of suppressing the tingling sensation is enhanced with the increase of the amount of the composition added within a certain compounding ratio. However, too much of the macromolecular humectant component may cause a decrease in the effect of suppressing stinging sensation and may cause burning and itching sensation, and the viscosity increases significantly, making it unsuitable for use in cosmetics.
As can be seen from the comparison of the data of the composition 2 and the composition 4, the inhibition effect of the composition on the stinging sensation is influenced by the different adding proportions of the small molecular humectant, wherein the inhibition effect on the stinging sensation is more obvious when the mass ratio of the urea to the trehalose is 1: 1.
As can be seen from the comparison of the data of the composition 2 and the composition 5, the ratio of the macromolecular humectant, the micromolecular humectant, the soothing agent and the gamma-aminobutyric acid also has an effect on the pain feeling inhibition effect. Wherein when the mass ratio of the gamma-aminobutyric acid, the bioglycan-1, the oat glucan, the sodium polyglutamate, the trehalose, the urea and the asiaticoside is 3:1:1:2:2:2:1, the composition has the best effect of relieving the tingling pain.
Moreover, as can be seen from the comparison of the data of composition 2 and composition 6, the preparation method of the composition also has a certain influence on the effect of the composition. Wherein, the composition prepared by the preparation method of the composition 6 has more obvious effect of inhibiting the side effect brought by the gamma-aminobutyric acid.
In conclusion, the invention compounds the gamma-aminobutyric acid and the composition according to a certain proportion by a specific method, and can effectively relieve the instant discomfort, especially the stabbing pain, brought by the use of the gamma-aminobutyric acid.
Example 3 anti-allergic efficacy test
Respectively and fully and uniformly mixing 5%, 10%, 15% and 20% of gamma-aminobutyric acid, 1g of bioglycan-1, 1g of oat glucan, 2g of sodium polyglutamate and water, fully swelling at 60 ℃, adding 2g of trehalose and 2g of urea, stirring until the trehalose and the urea are fully dissolved, cooling to 40 ℃, adding 1g of asiaticoside, and cooling to room temperature for later use.
The method in example 1 was used for testing, and the stimulation degree of gamma-aminobutyric acid with different content was observed, and the test results are shown in table 3.
TABLE 3 anti-allergic functional test
Content of gamma-aminobutyric acid (%) | Total number of people | Improvements in or relating to | Is not obvious | Weighting device |
5 | 10 | 10 | - | - |
10 | 10 | 10 | - | - |
15 | 10 | 10 | - | - |
20 | 10 | 8 | 2 | - |
As can be seen from the data in Table 3, the irritation caused by gamma-aminobutyric acid can be reduced within a certain range by the composition provided by the application, as the skin irritation degree is gradually increased along with the increase of the gamma-aminobutyric acid. Therefore, the composition effectively reduces the irritation of the gamma-aminobutyric acid and improves the safe use content of the gamma-aminobutyric acid in cosmetics, and the content of the gamma-aminobutyric acid in the composition can reach 15 percent at most.
Example 4 wrinkle removal efficacy test
Healthy volunteers with obvious wrinkles on their faces between the ages of 40-60 were selected and randomly divided into two groups of 20 persons, one group using the composition 6 product and the other group using the control group product for 8 weeks.
Before treatment, the face was cleaned and the condition of wrinkles on the skin before treatment was recorded using a VISIA skin detector. The VISIA skin test apparatus recorded the wrinkles after treatment and the test results are shown in table 4.
TABLE 4 comparison of VISIA wrinkle before and after treatment
Before treatment | After treatment | P value | |
Composition 6 | 24.98±5.72 | 3.71±2.17 | <0.01 |
Control group | 25.78±2.79 | 15.79±6.88 | <0.01 |
As can be seen from the data in Table 4, the wrinkle removing effect of the composition 6 is better than that of a control group, and the composition proves that the biological carbohydrate gum-1, the oat glucan, the sodium polyglutamate, the trehalose, the urea and the asiaticoside in the composition have better synergistic effect, can achieve the effects of layer-by-layer release and multiple wrinkle resistance while effectively relieving the side effect of the gamma-aminobutyric acid, has double synergistic effects of long-acting effect and short-acting effect, and has better wrinkle removing effect.
The above description is only an example of the present application and is not intended to limit the present application. Various modifications and changes may occur to those skilled in the art. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present application should be included in the scope of the claims of the present application.
Claims (10)
1. The composition for improving stimulation of gamma-aminobutyric acid is characterized by comprising 1-10 parts of gamma-aminobutyric acid, 1-20 parts of macromolecular humectant, 1-20 parts of micromolecular humectant and 0.1-10 parts of soothing agent by mass;
the molecular weight of the macromolecular humectant is 100-200 ten thousand daltons, and the molecular weight of the micromolecular humectant is less than 1000 daltons.
2. The composition according to claim 1, wherein the composition comprises 1-4 parts of gamma-aminobutyric acid, 1-5 parts of macromolecular humectant, 1-5 parts of small molecular humectant and 1-2 parts of soothing agent; preferably, 3 parts of gamma-aminobutyric acid, 4 parts of macromolecular humectant, 4 parts of micromolecular humectant and 1 part of soothing agent.
3. The composition of claim 1, wherein the macromolecular humectant is selected from one or more of biogel-1, oat glucan, sodium polyglutamate, and cellulose sulfate; preferably, the macromolecular humectant comprises bioglycan-1, oat glucan and sodium polyglutamate; more preferably, the mass ratio of the biological sugar gum-1 to the oat glucan to the sodium polyglutamate is (1-5): (1-5): (1-10); more preferably, the mass ratio of the biological sugar gum-1, the oat glucan and the sodium polyglutamate is 1:1: 2.
4. the composition of claim 1, wherein the small molecule humectant is selected from one or more of trehalose, urea, menthol lactate, 4-tert-butylcyclohexanol, water-soluble ceramide, and aloe vera juice; preferably, the micromolecular humectant is trehalose and urea; more preferably, the mass ratio of the trehalose to the urea is (1-10): (1-10); more preferably, the mass ratio of the trehalose to the urea is 1: 1.
5. the composition of claim 1, wherein the soothing agent is selected from one or more of asiaticoside and gentian root extract; more preferably, the soothing agent is asiaticoside.
6. A method of preparing the composition of claim 1, comprising the steps of: mixing and dissolving gamma-aminobutyric acid, a macromolecular humectant, a micromolecular humectant and a soothing agent by using water at the temperature of 40-70 ℃, and uniformly stirring to obtain the composition; preferably, the total amount is 100 parts by mass with water.
7. Use of a composition according to any one of claims 1 to 5 or obtained by the preparation method according to claim 6 for anti-wrinkle, whitening and/or moisturizing; preferably, the composition is for use in anti-wrinkle.
8. A cosmetic product comprising a composition according to any one of claims 1 to 5 or a composition prepared by a process according to claim 6.
9. The cosmetic according to claim 8, wherein the content of gamma-aminobutyric acid in the cosmetic is 0.1 to 15% by mass, preferably 0.5 to 15% by mass, more preferably 5.1 to 15% by mass.
10. The cosmetic according to claim 8, wherein the cosmetic is a mask, a cream, a lotion, a serum, a lotion, an eye cream and/or an introduction solution.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210181017.6A CN114376932B (en) | 2022-02-25 | 2022-02-25 | Composition for improving gamma-aminobutyric acid irritation as well as preparation method and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210181017.6A CN114376932B (en) | 2022-02-25 | 2022-02-25 | Composition for improving gamma-aminobutyric acid irritation as well as preparation method and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114376932A true CN114376932A (en) | 2022-04-22 |
CN114376932B CN114376932B (en) | 2024-04-16 |
Family
ID=81205900
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210181017.6A Active CN114376932B (en) | 2022-02-25 | 2022-02-25 | Composition for improving gamma-aminobutyric acid irritation as well as preparation method and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114376932B (en) |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107854355A (en) * | 2017-11-18 | 2018-03-30 | 上海煓梅生物科技有限公司 | A kind of anti-apolexis composition and its preparation method and application |
CN109700733A (en) * | 2017-10-26 | 2019-05-03 | 张家界茶坤缘生物科技开发有限公司 | Plant mask and preparation method thereof |
CN109820769A (en) * | 2019-03-14 | 2019-05-31 | 上海新高姿化妆品有限公司 | A kind of toner and preparation method thereof for having effects that moisturizing and releiving |
CN110123653A (en) * | 2019-05-28 | 2019-08-16 | 珠海萱嘉君行健康产业发展有限公司 | A kind of skin care item containing γ-aminobutyric acid matrine ionic liquid |
CN111419751A (en) * | 2020-04-23 | 2020-07-17 | 广州市科能化妆品科研有限公司 | Soothing composition, preparation method thereof and skin care product containing soothing composition |
CN112089664A (en) * | 2020-10-21 | 2020-12-18 | 广州华晟科创科技发展有限公司 | Essence with effects of resisting aging and removing deep wrinkles and preparation method thereof |
CN112773738A (en) * | 2021-02-23 | 2021-05-11 | 上海美浮特生物科技有限公司 | Moisturizing and relieving composition, preparation method thereof, skin care product and application |
CN113208947A (en) * | 2021-06-10 | 2021-08-06 | 广州睿森生物科技有限公司 | Anti-aging moisturizing composition and application thereof |
-
2022
- 2022-02-25 CN CN202210181017.6A patent/CN114376932B/en active Active
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109700733A (en) * | 2017-10-26 | 2019-05-03 | 张家界茶坤缘生物科技开发有限公司 | Plant mask and preparation method thereof |
CN107854355A (en) * | 2017-11-18 | 2018-03-30 | 上海煓梅生物科技有限公司 | A kind of anti-apolexis composition and its preparation method and application |
CN109820769A (en) * | 2019-03-14 | 2019-05-31 | 上海新高姿化妆品有限公司 | A kind of toner and preparation method thereof for having effects that moisturizing and releiving |
CN110123653A (en) * | 2019-05-28 | 2019-08-16 | 珠海萱嘉君行健康产业发展有限公司 | A kind of skin care item containing γ-aminobutyric acid matrine ionic liquid |
CN111419751A (en) * | 2020-04-23 | 2020-07-17 | 广州市科能化妆品科研有限公司 | Soothing composition, preparation method thereof and skin care product containing soothing composition |
CN112089664A (en) * | 2020-10-21 | 2020-12-18 | 广州华晟科创科技发展有限公司 | Essence with effects of resisting aging and removing deep wrinkles and preparation method thereof |
CN112773738A (en) * | 2021-02-23 | 2021-05-11 | 上海美浮特生物科技有限公司 | Moisturizing and relieving composition, preparation method thereof, skin care product and application |
CN113208947A (en) * | 2021-06-10 | 2021-08-06 | 广州睿森生物科技有限公司 | Anti-aging moisturizing composition and application thereof |
Also Published As
Publication number | Publication date |
---|---|
CN114376932B (en) | 2024-04-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5010775B2 (en) | Use of ellagic acid and its derivatives in cosmetics and dermatology | |
CN112494406A (en) | Whitening and freckle-removing cosmetic and preparation method thereof | |
KR101140039B1 (en) | A composition that contains ginsenoside F1 and/or Compound K for skin external application | |
CN105663020A (en) | Spraying water with long-acting moisture-preserving capacity and preparation method thereof | |
CN112656713A (en) | Cosmetic composition containing hyaluronic acid and/or derivatives thereof, and preparation method and application thereof | |
CN115517999B (en) | Anti-aging composition and application thereof in beauty and skin care | |
CN115137665A (en) | Composition with long-acting moisturizing and relieving effects and application thereof | |
CN115531272B (en) | Antioxidant composition derived from alpine plants and preparation method and application thereof | |
CN110721148A (en) | Multidirectional pulling and tightening polypeptide essence and preparation method thereof | |
CN114042027A (en) | Composition with sensitive muscle repairing effect and preparation method and application thereof | |
CN112773761A (en) | Cosmetic composition, essence and preparation method thereof | |
CN116617106A (en) | Protopanaxatriol saponin allergy-relieving repairing composition, and preparation method and application thereof | |
CN111012699A (en) | Antioxidant oil-controlling emulsion containing fucoidan-kelp extract | |
CN114376932B (en) | Composition for improving gamma-aminobutyric acid irritation as well as preparation method and application thereof | |
CN116098840A (en) | Use of white truffle extract or composition containing same | |
CN112245324B (en) | Cosmetic with moisturizing function and preparation method and application thereof | |
CN111920703B (en) | Hyaluronic acid-containing composition for skin care and application thereof | |
CN109350584B (en) | Fermented raw juice of traditional Chinese medicine composition with powerful moisturizing effect and preparation and application thereof | |
JP2002516836A (en) | Use of sophorolipids containing diacetylated lactones as stimulants of skin fibroblast metabolism | |
KR20050097578A (en) | Cosmetic composition containing the zizyphus jujuba fruit extract and walnut extract for moisturizing effect on the skin | |
CN112641685A (en) | Moisturizing and circulation promoting essence and preparation method thereof | |
CN115444772B (en) | Moisturizing and whitening composition and application thereof in radio frequency beauty and medical skin care | |
CN117530902B (en) | Acne-removing and inflammation-diminishing composition containing sulfated schizophyllan and application of composition | |
CN118105311B (en) | Plant small molecule peptide composition with wrinkle removing effect, preparation and preparation method thereof | |
CN112220705B (en) | Moisturizing cosmetic with pure natural components |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A composition for improving the irritability of gamma aminobutyric acid and its preparation method and application Granted publication date: 20240416 Pledgee: Bank of Beijing Co.,Ltd. Jinan Branch Pledgor: SHANDONG HUAWUTANG BIOTECHNOLOGY Co.,Ltd. Registration number: Y2024980030933 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |